Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.
Journal: Journal for immunotherapy of cancer
Published: May 28, 2026
Biomarker study of pembrolizumab in patients with advanced rare cancers.
Journal: Cell reports. Medicine
Published: September 24, 2025
Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors.
Journal: ESMO open
Published: February 28, 2025
A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies.
Journal: The oncologist
Published: August 22, 2024
Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial.
Journal: Journal of immunotherapy and precision oncology
Published: March 18, 2024
A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma.
Journal: Journal of immunotherapy and precision oncology
Published: January 25, 2024
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy.
Journal: Journal for immunotherapy of cancer
Published: August 04, 2023
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience.
Journal: The oncologist
Published: November 07, 2022
Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
Journal: Advances in experimental medicine and biology
Published: January 01, 2022
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
Journal: Investigational new drugs
Published: October 27, 2021
Last Updated: 09/26/2026